BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer
Cellular and Molecular Life Sciences, ISSN: 1420-9071, Vol: 74, Issue: 2, Page: 231-243
2016
- 24Citations
- 53Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- CrossRef6
- Captures53
- Readers53
- 53
Review Description
Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84982883579&origin=inward; http://dx.doi.org/10.1007/s00018-016-2320-0; http://www.ncbi.nlm.nih.gov/pubmed/27491296; http://link.springer.com/10.1007/s00018-016-2320-0; https://dx.doi.org/10.1007/s00018-016-2320-0; https://link.springer.com/article/10.1007/s00018-016-2320-0; https://link.springer.com/content/pdf/10.1007%2Fs00018-016-2320-0.pdf; http://link.springer.com/article/10.1007/s00018-016-2320-0/fulltext.html; http://link.springer.com/article/10.1007%2Fs00018-016-2320-0; http://link.springer.com/content/pdf/10.1007/s00018-016-2320-0.pdf; http://link.springer.com/content/pdf/10.1007/s00018-016-2320-0
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know